Internal Med Medical News about Olmesartan

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The effects of an olmesartan medoxomil–based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older
The Journal of Clinical Hypertension, 07/01/09

Kereiakes DJ et al. – An olmesartan medoxomil (OM)-based treatment algorithm effectively lowers blood pressure (BP) in an elderly pt population throughout 24-hr dosing interval without compromising tolerability.

Methods

Study of the effect of OM ± hydrochlorothiazide (HCTZ) on mean 24-hr ambulatory BP, mean seated cuff (Se)BP, and SeBP goal achievement in hypertensive pts age ≥65 yrs
After 2- to 3-wk placebo run-in, OM 20 mg, uptitrated to 40 mg, then added HCTZ 12.5 mg to 25 mg stepwise at 3-wk intervals if SeBP remained ≥120/70 mm Hg
Primary endpoint: change from baseline in mean 24-hr ambulatory systolic BP

Results

At study end, mean 24-hr ambulatory BP decreased by 25.7/12.3 mm Hg (150 pts) and mean SeBP by 25.4/10.5 mm Hg (176 pts)
Drug-related treatment-emergent adverse events, most commonly dizziness (3.4%), hypotension (2.2%), and headache (1.1%), in 11.8% of pts

<< Previous
Rheumatoid arthritis is linked to oral bacteria: Etiological...

Next >>
Hyponatremia in heart failure: The role of arginine vasopressin...